925449-98-5

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 87491-79-0 1-[(chloromethyl)sulfonyl]naphthalene 
• 82420-35-7 2-(bromomethyl)-4-fluoro-1-nitrobenzene 
• 64326-13-2 sodium naphthalene-1-sulfinate 

Downstream Products

• 1232361-12-4 C₂₅H₂₇N₃O₆S 
• 1086838-55-2 t-butyl 1-{3-[(naphth-1-ylsulfonyl)methyl]-4-nitrophenyl}-piperidin-4-ylcarbamate 
• 1232361-11-3 C₂₆H₂₉N₃O₆S 
• 925450-11-9 2-[3-(naphthalene-1-sulfonylmethyl)-4-nitro-phenoxy]-ethanol 
• 1199795-04-4 benzyl 4-(3-((naphthalen-1-ylsulfonyl)methyl)-4-nitrophenyl)-piperazine-1-carboxylate 
• 1086838-51-8 (R)-t-butyl 1-{[3-(naphth-1-ylsulfonyl)methyl]-4-nitrophenyl}pyrrolidin-3-ylcarbamate 
• 925449-99-6 3-[3-(naphthalene-1-sulfonylmethyl)-4-nitro-phenoxy]-propan-1-ol 

Relevant academic research and scientific papers

5-piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists

As part of our efforts to develop agents for CNS diseases, we have been focused on the 5-HT6 receptor in order to identify potent and selective ligands for cognitive enhancement. Herein we report the identification of a novel series of 5-piperazinyl-3-sulfonylindazoles as potent and selective 5-HT6 antagonists. The synthesis, SAR, and pharmacokinetic and pharmacological activities of some of the compounds including 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (WAY-255315 or SAM-315) will be described.

5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists

Novel 5-cyclic amine-3-arylsulfonylindazoles were prepared, and several analogues within this class have been identified as high-affinity 5-HT 6 receptor ligands with improved pharmacokinetic and pharmacological properties. One selected example, 18b, showed good brain penetrability and a generally favorable pharmacokinetic profile with procognitive efficacy in the rat novel object recognition assay. The synthesis and structure-activity relationship of this potent class are discussed.

1-SUBSTITUTED-3-(NAPHTHALEN-1-YLSULFONYL)-5-(PIPERAZIN-1-YL)-1H-INDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS

The disclosure is directed to compounds of Formula I: processes for their preparation, treatment of central nervous system (CNS) disorders and methods for the modulation of 5HT6 activity.

PROCESS FOR THE MANUFACTURE OF BENZYLSULFONYLARENES

The present invention provides a process for the manufacture of an arylmethyl-sulfonylarene, R1CH2SO2R2, wherein R1 and R2 are each independently an optionally substituted phenyl or naphthyl group which process comprises reacting an arylmethylhalide, R1CH2-Hal wherein R1 is as defined hereinabove and Hal is Cl, Br or I with a sodium arylsulfinate R2SO2Na wherein R2 is as defined hereinabove in the presence of a base optionally in the presence of a solvent. Also provided is the use of the inventive process in the manufacture of a 3-arylsulfonylindazole 5-HT6 ligand.

AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.

Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.